vimarsana.com
Home
Live Updates
Yazeed sawalha
Live Breaking News & Updates on Yazeed sawalha
Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T
But where mosunetuzumab/polatuzumab vedotin would fit among available options remains a question
United-states
,
Yazeed-sawalha
,
Greg-laub
,
Kami-maddocks
,
David-bond
,
Ohio-state-university-wexner-medical-center
,
American-society-of-hematology
,
American-society
,
Medpage-today
,
Favorable-safety-profile
,
Refractory-largeb-cell-lymphoma
,
Primary-analysis
Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma
'Safety profile is one of the real advantages' of non-covalent BTK inhibitor, says panelist
United-states
,
American
,
Yazeed-sawalha
,
David-bond
,
Kami-maddocks
,
Greg-laub
,
American-society-of-hematology
,
Ohio-state-university-wexner-medical-center
,
American-society
,
Medpage-today
,
Highly-selective
,
Refractory-follicular-lymphoma
Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma
Study results show impressive efficacy, favorable safety profile in the second line
United-states
,
Greg-laub
,
Kami-maddocks
,
David-bond
,
Yazeed-sawalha
,
Ohio-state-university-wexner-medical-center
,
Transcend
,
American-society-of-hematology
,
American-society
,
Medpage-today
,
Senior-director
,
Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients
Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study
United-states
,
Greg-laub
,
David-bond
,
Kami-maddocks
,
Yazeed-sawalha
,
American-society-of-hematology
,
Ohio-state-university-wexner-medical-center
,
American-society
,
Medpage-today
,
Senior-director
,
Positive Results for Odronextamab in Relapsed/Refractory DLBCL
But experts aren't sure where it would fit in with currently approved bispecifics
United-states
,
Kami-maddocks
,
Kamij-maddocks
,
Yazeed-sawalha
,
Yazeedy-sawalha
,
Ohio-state-university-wexner-medical-center
,
Ohio-state-university-james-comprehensive-cancer-center
,
Ohio-state-university
,
American-society-of-hematology
,
American-society
,
Medpage-today
,
Im-yazeed-sawalha
Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years
Bispecific antibody also shows high response rates in frontline setting
United-states
,
Ohio
,
Ohio-state-university
,
Mosunetuzumab-lunsumio
,
Kamij-maddocks
,
Yazeedy-sawalha
,
Greg-laub
,
Kami-maddocks
,
Yazeed-sawalha
,
Ohio-state-university-wexner-medical-center
,
American-society-of-hematology
,
Ohio-state-university-james-comprehensive-cancer-center